Revolution Medicines’ stock slid 6.3% Thursday after newly released FDA review documents sparked investor unease around ...
After a year of rocky financials and trial readouts, Quince Therapeutics is charting a new path forward and relaunching with ...
With a Friday go-ahead from the FDA, another key piece of Teva’s innovation revamp strategy has fallen into place, further ...
All told, GSK is plugging more than $800 million into an overhaul of its facilities in Upper Merion Township, where ...
Novartis bought an mRNA-coded autoimmune T-cell engager candidate for up to $7.8 billion, as Shionogi offered $2 billion to ...
Promotional interactions between clinicians and pharmaceutical companies are probably associated with harmful outcomes, ...
With the FDA approval of Zenbexus this summer, Bristol Myers Squibb checked off two notable ‘firsts,’ scoring the inaugural ...
As the Trump administration advances plans to bring its “most favored nation” drug pricing model to Medicare Part B, the ...
Generic drugmaker Viatris is beefing up its pain medicine portfolio with a $1.65 billion deal to buy Pacira BioSciences and ...
The successes of the GLP-1 class for chronic weight management “introduced consumer overlay over a historically physician-driven therapeutic area,” Pothier explained, noting that despite the potency ...
Pfizer bagged a coveted first-line maintenance approval for Tukysa. In combination with HER2 antibody drugs, the treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results